EPAS1 and renal cell adenocarcinoma: Approved by the FDA in 2021 for the treatment of renal cell carcinoma (RCC) in patients with VHL disease, Belzutifan, is a hypoxia-inducible factor 2-alpha inhibitor that has continued to show promising responses as a potential therapeutic option for RCC and other VHL-related tumors [5–8].